Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

2000 • 856 citations

Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly¹

1998 • 599 citations

Determinants of clinical outcome and survival in acromegaly

1994 • 573 citations

An audit of outcome of treatment in acromegaly

1993 • 476 citations

Transsphenoidal Microsurgery for Growth Hormone-Secreting Pituitary Adenomas: Initial Outcome and Long-Term Results

1998 • 347 citations

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1995 • 246 citations

Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR^®) for the management of acromegaly

1998 • 139 citations

Growth Hormone (GH) Receptor Blockade with a PEG-Modified GH (B2036-PEG) Lowers Serum Insulin-Like Growth Factor-I but Does Not Acutely Stimulate Serum GH¹

1999 • 109 citations

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.

1996 • 105 citations

MEDICAL THERAPY FOR ACROMEGALY

1999 • 88 citations

A comparison of lanreotide and octreotide LAR for treatment of acromegaly

1999 • 86 citations

Current Therapy for Acromegaly

2000 • 39 citations

Somatuline LA: a new treatment for acromegaly.

1998 • 6 citations